1. Reply To the Editor, Re: Bicakli et al. Adjuvant chemotherapy may contribute to an increased risk for metabolic syndrome in patients with breast cancer. J Oncol Pharm Pract, published online September 2014. DOI: 10.1177/1078155214551315. (August 2015) Authors: Bicakli, Derya Hopanci; Varol, Umut; Degirmenci, Mustafa; Tunali, Didem; Cakar, Burcu; Durusoy, Raika; Karaca, Burcak; Sanli, Ulus Ali; Uslu, Ruchan Journal: Journal of oncology pharmacy practice Issue: Volume 21:Number 4(2015:Dec.) Page Start: 318 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. Safety and efficacy of regorafenib in patients with treatment-refractory metastatic colorectal cancer in Turkey: the single-arm, open-label REGARD study. Issue 3 (26th March 2020) Authors: Dane, Faysal; Ozgurdal, Kirhan; Yalçın, Şuayib; Benekli, Mustafa; Aykan, Nuri Faruk; Yücel, İdris; Özkan, Metin; Evrensel, Turkkan; Sevinç, Alper; Coskun, Hasan Şenol; Sanli, Ulus Ali; Kara, Ismail Oguz; Yumuk, Perran Fulden Journal: BMJ open Issue: Volume 10:Issue 3(2020) Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗